Frontier Medicines
PrivateLast Round
Series C
Feb 22, 2024
Total Funding Raised
$255.5M
Company Overview
Frontier Medicines operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series C round in February 2024.
Frontier Medicines is a clinical-stage biopharmaceutical company that develops precision medicines for genetically-defined patient populations by utilizing a proprietary chemoproteomics and machine learning platform to target previously 'undruggable' proteins.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Precision Medicine, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Frontier Medicines Comparables
Compare Frontier Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genesis Molecular AI | 85% | |
| Iambic Therapeutics | 85% | |
| Antares Therapeutics | 85% |
For institutional investors. Book with your work email.
Frontier Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Feb 22, 2024 | ||||
| Series B | Jul 19, 2021 | ||||
| Series A | Jun 25, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Frontier Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series B, Series C, Series A |
| MPM Capital | Series C, Series B, Series A |
| RA Capital Management | Series C, Series A, Series B |
| DCVC Bio | Series C, Series A |
| Deep Track Capital | Series C, Series B |
| MPM BioImpact | Series C, Series B, Series A |
| Droia Ventures | Series B, Series C, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 31, 2026
Partnered with LG Chem for FMC-220, a p53 activator.
- Mar 17, 2026
Launched the AI-powered Frontier Platform at AACR Annual Meeting 2026.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 4, 2026
Frontier Medicines Corporation plans to present preclinical FMC-242 data at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, from Nov 18th-20th '26.
- attends_eventOct 25, 2026
Frontier Medicines presents results from the Phase 1 monotherapy portion of its PROSPER trial at the European Society for Medical Oncology Congress 2026 in Spain.
- attends_eventOct 25, 2026
Frontier Medicines presents first clinical data for FMC-376 during a rapid oral session at ESMO Congress 2026 in Madrid, Spain, on Oct 25th '26.
For institutional investors. Book with your work email.
Frontier Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Frontier Medicines's valuation, stock price, and market status.
Is Frontier Medicines a public or private company?
Frontier Medicines is a private company.
What is the current stock price of Frontier Medicines?
Frontier Medicines is a private company, so its shares have no public market price. Caplight tracks Frontier Medicines's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Frontier Medicines worth (valuation)?
Valuation information for Frontier Medicines is not publicly available.
Can I buy Frontier Medicines stock?
Frontier Medicines shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Frontier Medicines's last funding round?
Frontier Medicines's most recent funding round was Series C on February 22, 2024.
Who are the main investors in Frontier Medicines?
Key investors in Frontier Medicines include Deerfield Management, MPM Capital, RA Capital Management, MPM BioImpact, Droia Ventures.
Will Frontier Medicines IPO soon?
No public IPO plans have been announced for Frontier Medicines.
How can I track Frontier Medicines secondary market activity?
Caplight tracks bids, offers, and trades in Frontier Medicines's shares on secondary markets.